July 05, 2016

Pankaj Patel appointed as the Chairman of the Board of Bayer CropScience Limited w.e.f. July 5, 2016

At the Board of Directors meeting of Bayer CropScience Limited held on July 5, 2016, Pankaj Patel was appointed as the Non-Executive Director and elected as the Chairman of the Board, with immediate effect. Pankaj Patel is the Chairman and Managing Director of Zydus Cadila, one of India’s leading pharmaceutical groups and an innovation-driven, global healthcare company with operations in more than 50 countries worldwide. With an experience spanning over 40 years in the Indian pharmaceutical industry, Mr. Patel combines both research and techno-commercial expertise.

 

Mr. Patel is also the Chairman of Bayer Zydus Pharma Private Limited – a joint venture company between Bayer (South East Asia) Pte Ltd and Cadila Healthcare Limited.

 

 

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.in

 

Media contact
Aloke Pradhan

Corporate Communications, Bayer Group in India
Tel.: +9122-25311234; E-mail: aloke.pradhan@bayer.com

 

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.